Aug 14, 2024 10:50 pm EDT Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
Jun 14, 2024 11:00 am EDT LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
Jun 6, 2024 8:30 am EDT Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
Jun 3, 2024 8:30 am EDT LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
May 8, 2024 9:25 am EDT LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
Mar 27, 2024 8:30 am EDT NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
Mar 21, 2024 8:30 am EDT LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Feb 27, 2024 8:30 am EST Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
Feb 26, 2024 8:30 am EST LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
